Comparison of Different Liquid Chromatography-Based Purification Strategies for Adeno-Associated Virus Vectors.
adeno-associated virus
affinity chromatography
column purification
empty capsids
ion exchange chromatography
rAAV vector
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
18 May 2021
18 May 2021
Historique:
received:
29
03
2021
revised:
10
05
2021
accepted:
11
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Recombinant adeno-associated virus (rAAV) vectors have evolved as one of the most promising technologies for gene therapy due to their good safety profile, high transduction efficacy, and long-term gene expression in nondividing cells. rAAV-based gene therapy holds great promise for treating genetic disorders like inherited blindness, muscular atrophy, or bleeding disorders. There is a high demand for efficient and scalable production and purification methods for rAAVs. This is particularly true for the downstream purification methods. The current standard methods are based on multiple steps of gradient ultracentrifugation, which allow for the purification and enrichment of full rAAV particles, but the scale up of this method is challenging. Here, we explored fast, scalable, and universal liquid chromatography-based strategies for the purification of rAAVs. In contrast to the hydrophobic interaction chromatography (HIC), where a substantial amount of AAV was lost, the cation exchange chromatography (CEX) was performed robustly for multiple tested serotypes and resulted in a mixture of full and empty rAAVs with a good purity profile. For the used affinity chromatography (AC), a serotype dependence was observed. Anion exchange chromatography (AEX) worked well for the AAV8 serotype and achieved high levels of purification and a baseline separation of full and empty rAAVs. Depending on the AAV serotype, a combination of CEX and AEX or AC and AEX is recommended and holds promise for future translational projects that require highly pure and full particle-enriched rAAVs.
Identifiants
pubmed: 34070226
pii: pharmaceutics13050748
doi: 10.3390/pharmaceutics13050748
pmc: PMC8158740
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft (DFG)-funded cluster of excellence Centre for Integrated Protein Science Munich (CIPSM)
ID : EXC-114
Références
Viruses. 2020 Jun 20;12(6):
pubmed: 32575696
Hum Gene Ther. 2003 Jul 20;14(11):1079-88
pubmed: 12885347
Mol Ther Methods Clin Dev. 2018 May 08;10:1-7
pubmed: 30073177
Mol Ther. 2014 Jan;22(1):1-2
pubmed: 24384906
Hum Gene Ther Methods. 2015 Dec;26(6):228-42
pubmed: 26414997
Mol Ther. 2012 Feb;20(2):443-55
pubmed: 22068425
J Virol. 2013 May;87(9):4974-84
pubmed: 23427155
Mol Ther Methods Clin Dev. 2021 Mar 23;21:341-356
pubmed: 33898632
Hum Gene Ther Methods. 2012 Feb;23(1):56-64
pubmed: 22428980
Hum Gene Ther Methods. 2012 Jun;23(3):198-203
pubmed: 22816378
Viruses. 2021 Jan 13;13(1):
pubmed: 33450892
Hum Gene Ther. 2002 Jul 1;13(10):1235-43
pubmed: 12133276
FEBS J. 2019 Dec;286(24):4964-4981
pubmed: 31330090
Curr Pharm Biotechnol. 2015;16(8):684-95
pubmed: 25941887
Hum Gene Ther. 2004 Jan;15(1):93-128
pubmed: 14965381
EMBO Mol Med. 2021 Apr 9;13(4):e13392
pubmed: 33616280
Biotechnol Bioeng. 2020 Oct;117(10):3199-3211
pubmed: 32573761
Mol Ther. 2006 Apr;13(4):823-8
pubmed: 16473554
Virology. 2008 Nov 25;381(2):194-202
pubmed: 18834608
J Virol Methods. 2007 Mar;140(1-2):183-92
pubmed: 17196264
Mol Ther. 2018 Dec 5;26(12):2848-2862
pubmed: 30343890
Mol Ther Methods Clin Dev. 2018 Nov 01;11:180-190
pubmed: 30533449
Gene Ther. 2010 Apr;17(4):503-10
pubmed: 19956269
Mol Ther Methods Clin Dev. 2019 Sep 26;15:257-263
pubmed: 31720304
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):343-52
pubmed: 25615882
Hum Gene Ther. 2017 Nov;28(11):982-987
pubmed: 28825330
Biomedicines. 2014 Mar 03;2(1):80-97
pubmed: 28548061
Hum Gene Ther. 2000 Oct 10;11(15):2079-91
pubmed: 11044910
Front Neurosci. 2016 Jul 28;10:356
pubmed: 27516733
Mol Ther Methods Clin Dev. 2019 May 18;13:526-531
pubmed: 31194094
Gene Ther. 2005 Oct;12 Suppl 1:S51-61
pubmed: 16231056
Gene Ther. 2005 Oct;12 Suppl 1:S5-17
pubmed: 16231055
Hum Gene Ther Methods. 2017 Jun;28(3):101-108
pubmed: 28322595
Cell. 1983 May;33(1):135-43
pubmed: 6088052
Methods Mol Biol. 2018;1715:33-46
pubmed: 29188504
Mol Ther Methods Clin Dev. 2017 Dec 22;9:33-46
pubmed: 29349097
Mol Ther. 2013 Mar;21(3):509-19
pubmed: 23358189
Biotechnol J. 2021 Jan;16(1):e2000015
pubmed: 33002276
J Virol Methods. 2004 Nov;121(2):209-15
pubmed: 15381358
BioDrugs. 2017 Aug;31(4):317-334
pubmed: 28669112
Mol Ther Methods Clin Dev. 2016 Mar 30;5:16019
pubmed: 27069952
Prog Retin Eye Res. 2014 Nov;43:108-28
pubmed: 25124745